Based in the US, KAI will provide Navitas will its existing relationships with clinical sites as well and its network of service providers in the US and in Africa. According to a spokesperson for Navitas, KAI will continue to work with the US government through clinical research contracts in areas of emergent and epidemic infectious diseases with a priority on the African continent supported by partners and sites throughout Africa.
The spokesperson added that through this agreement Navitas’ ability to interact with KAI’s network will put the company in a “unique standpoint in serving federal agenices like the US Food and Drug Administration (FDA), National Institute of Health (NIH), Center for Disease Control (CDC), and Department of defense.”
Per the acquisition, Navitas will also obtain KAI’s e-clinical solutions and patient registries which will enable the company to expand its Phase II and III capabilities in North America and add to its offerings in Europe.
The spokesperson added, “The addition of KAI’s capabilities translates to global trial capabilities across North America, Europe and APAC markets. Combining these operational and TA capabilities with our proprietary AI driven OneClincial platform allows us to be a great partner to small and mid-tier customers as well as to large pharma.”